In bid to extend cash runway, Cara to lay off workers, discontinue PhIII program in chronic kidney disease
Cara Therapeutics is cutting its workforce by nearly 50% and ending a Phase III program investigating an oral version of its opioid peptide in patients with chronic kidney disease.
The Stamford, CT-based biotech has been investigating oral difelikefalin against different diseases that cause pruritus — the medical term for itching — but it has faced multiple hurdles in recent months.
By conducting layoffs that include the exit of its head of R&D Frédérique Menzaghi and shuttering its chronic kidney disease program, the company now expects to extend its cash runway into 2026. It had 106 employees as of March 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.